1
Paul Edward Aldrich, Argyrios Georgios Arvanitis, Robert Scott Cheeseman, Robert John Chorvat, Thomas Eugene Christos, Paul Joseph Gilligan, Dimitri Emil Grigoriadis, Carl Nicholas Hodge, Paul John Krenitsky, Everett Latham Scholfield, Sang William Tam, Zelda Rakowitz Wasserman: 1N-alkyl-n-arylpyrimidinamines and derivatives thereof. DuPont Pharmaceuticals Company, Robert W Black, Kenneth B Rubin, Kalim S Fuzail, January 29, 2002: US06342503 (66 worldwide citation)

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppressi ...


2

3
Parthasarathi Rajagopalan, Robert John Chorvat, Rajagopal Bakthavatchalam, James Peter Beck, Paul Joseph Gilligan, Richard Eric Olson: 6-aryloxy and arylthiopurines. DuPont Pharmaceuticals Company, Kenneth B Rubin, Kalim S Fuzail, July 10, 2001: US06258809 (12 worldwide citation)

Novel compounds and pharmaceutical compositions thereof, and methods of using same in treating anxiety, depression, and other psychiatric and neurological disorders. The novel compounds provided by this invention are those of the following formulae:


4
Kevin A Gray, Lishan Zhao, Michelle H Cayouette: Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them. BP Corporation North America, Kalim S Fuzail, January 24, 2012: US08101393 (11 worldwide citation)

The invention provides polypeptides having any cellulolytic activity, e.g., a cellulase activity, a endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a β-xylosidase, an arabinofuranosidase, and/or an oligomerase activity, polynucleotides encoding these polypeptides, and ...


5

6

7
Pancras C Wong, Shaker A Mousa: Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders. Bristol Myers Squibb Pharma Company, Robert W Black, Rosemarie Wilk Orescan, Kalim S Fuzail, February 12, 2002: US06346517 (9 worldwide citation)

This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders.


8

9
Jeffrey A Miller, Elizabeth C Arner, Robert A Copeland, Gary L Davis, Ruiqin Liu, Michael Pratta, Micky D Tortorella: Assays and peptide substrate for determining aggrecan degrading metallo protease activity. Bristol Myers Squibb Pharma Company, Karen Konrad, Kenneth B Rubin, Kalim S Fuzail, December 4, 2001: US06326162 (7 worldwide citation)

This invention is directed to assays to determine the presence or absence of proteins that exhibit aggrecanase or ADMP activity. This invention also relates to peptides that acts as a substrates for ADMPs, their use in various assays to determine the presence or absence of ADMP activity, and their u ...


10
Jeffery S Carter: Prodrugs of COX-2 inhibitors. Pharmacia Corporation, David B Fournier, Kalim S Fuzail, September 2, 2003: US06613790 (6 worldwide citation)

A compound of Formula (I), or a pharmaceutically-acceptable salt thereof, suitable for use in the treatment of a cyclooxygenase-2 mediated disease is provided.



Click the thumbnails below to visualize the patent trend.